US to stop financial support of global vaccine alliance Gavi, health secretary says
Live Events
(You can now subscribe to our
(You can now subscribe to our Economic Times WhatsApp channel
Health Secretary Robert F. Kennedy Jr. said on Wednesday that the U.S. government will no longer contribute to Gavi, accusing the group that helps buy vaccines for the world's poorest children of ignoring safety, without providing evidence.In a video statement seen by Reuters and shown at a Gavi fundraising event in Brussels, Kennedy - a long-time vaccine skeptic - also accused the organization of making questionable recommendations around COVID-19 vaccines, and raised concerns about the DTPw (diphtheria-tetanus-whole cell pertussis) vaccine.Gavi said in a statement that safety was key, and that it acts in line with World Health Organization recommendations. It has full confidence in the DTPw vaccine, which has contributed to halving child mortality in the countries it supports since 2000, the statement continued."I call on Gavi today to re-earn the public trust, and to justify the $8 billion that America has provided in funding since 2001," Kennedy said in the video, saying Gavi should consider all available science."Until that happens, the United States won't contribute more," he said.The details of the video were first reported by Politico.Gavi said it "fully concurs with the Secretary for Health and Human Services on the need to consider all available science, and remains committed to continuing an evidence-based and scientific approach to its work and investment decisions, as it always has done."Gavi leaders, donors and countries it works with are in Brussels for the organization's pledging summit, where the alliance aims to raise $9 billion for its work from 2026-30.Kennedy said in the video that he admired much of Gavi's work, particularly its efforts to make medicines affordable worldwide."Unfortunately, in its zeal to promote universal vaccination, it has neglected the key issue of vaccine safety," he added."Gavi's utmost concern is the health and safety of children," the group's statement responded.The Trump administration has previously indicated that it planned to cut its funding for Gavi, representing around $300 million annually, as part of a wider pullback from international aid.President Donald Trump's nominee for director of the Centers for Disease Control and Prevention , Susan Monarez, was asked about the Gavi decision at a Senate hearing on Wednesday."I believe the global health security preparedness is a critical and vital activity for the United States," she said."I think that we need to continue to support promotion of utilization of vaccines," she continued, adding that she was not involved in that decision-making and would look into it if confirmed.Other donors, including Germany, Norway, and the Gates Foundation, have already pledged money in recent days for Gavi's future work.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
an hour ago
- Mint
FDA expands warning about rare heart side effect in two leading Covid vaccines
The Food and Drug Administration has mandated that Pfizer and Moderna expand warning labels on their mRNA COVID-19 vaccines (Comirnaty and Spikevax) to highlight a rare risk of myocarditis and pericarditis, which are heart inflammation conditions, primarily in males aged 16–25. The updated labels now cite an incidence rate of 38 cases per million doses in this demographic, up from prior warnings focused on ages 12–17 (Pfizer) and 18–24 (Moderna). For all recipients under 65, the overall risk remains low at nearly 8 cases per million doses. This move follows FDA analysis of 2023–2024 vaccine safety data, including insurance claims and a study showing persistent cardiac MRI abnormalities in some patients five months post-diagnosis. The CDC, however, maintains that such cases are rare, typically resolve quickly, and are less severe than those caused by COVID-19 infection itself. Policy clash and political tensions underpin new warnings The FDA's decision conflicts with prior CDC assessments that found no increased myocarditis risk in vaccine injury databases since 2022. It also aligns with broader efforts by Health Secretary Robert F. Kennedy Jr.'s administration to tighten vaccine oversight. Kennedy recently replaced all 17 CDC advisory panel members with appointees, including anti-vaccine advocates, and FDA Commissioner Marty Makary, a critic of COVID-19 booster mandates, has restricted annual shots to high-risk groups (e.g., senior citizens). Also Read | Nestle says it will remove artificial dyes from US foods by 2026 Critics argue the label expansion overlooks context: Studies confirm COVID-19 infection poses a 16-fold higher myocarditis risk than vaccination, and most post-vaccine cases are mild, resolving with anti-inflammatory treatment. Yale researchers note the inflammation is transient, not autoimmune, allowing full recovery. Expert backlash and global safety perspectives Medical experts condemn the FDA's approach as misleading. 'They are right to suggest that we need to consider myocarditis risks associated with the vaccine, but what they propose is exactly the wrong solution,' said Dr. Robert Morris of the University of Washington. 'We should be investigating who is prone to myocarditis to see if we can predict and mitigate that risk," according to a report by AP.
The Hindu
3 hours ago
- The Hindu
Bharat Biotech, GSK to cut malaria vaccine price by more than half by 2028
Bharat Biotech International Ltd and GSK plc on Wednesday said they will reduce the price of the world's first malaria vaccine for children 'RTS,S' developed by GSK, PATH and partners, by more than half to less than USD 5 progressively by 2028. Announced as part of their commitment to the Vaccine Alliance (Gavi), the two companies said the price reduction is driven by process improvements, expanded production capacity, cost-effective manufacturing, and minimal profit margins. Lower vaccine cost through collaboration The announcement forms part of pledges to Gavi for its next replenishment phase -- Gavi 6.0, 2026-2030 -- by both companies, they said in a joint statement. "This pledge to Gavi 6.0 is more than a pricing announcement. It is a commitment to global equity, innovation, and collaboration. Through this historic announcement, we aim to change the course of malaria burden for millions of children and families," Bharat Biotech International Ltd (BBIL) Executive Chairman Krishna Ella said. Further, he said, "By joining forces with GSK, and working closely with Gavi, and the WHO, we are taking a real step toward closing the gap between vaccine supply and the urgent needs of children at risk of malaria." GSK Chief Global Health Officer Thomas Breuer said the company had partnered with Bharat Biotech in 2021 with a common goal of finding a sustainable solution to get ahead of malaria. "Today, we announce GSK's contribution to the long-term price ambition of the world's first malaria vaccine, a key milestone achieved through collaboration with Bharat Biotech and partners from Gavi, PATH and the WHO," he said. Breuer added, "This demonstrates our commitment to changing the trajectory of infectious diseases like malaria, making a difference in the lives of children and families across Africa." The GSK team has worked hand in hand with Bharat Biotech to transfer the vaccine manufacturing technology while simultaneously implementing crucial improvements in manufacturing efficiencies, resulting in the latest pledge to the Gavi replenishment, he noted. Boosting malaria immunisation drive With Gavi's support, 12 endemic countries in Africa will be introduced to RTS,S through routine immunisation programmes by the end of 2025. RTS,S was the first malaria vaccine recommended by the World Health Organization (WHO) in 2021. Since then, GSK has made significant investments to enhance production capacity and efficiency and undertake the planned technology transfer to Bharat Biotech, the statement said. In parallel, Bharat Biotech has invested over USD 200 million in new, higher-output manufacturing facilities, product development and technology transfers. "These enhancements have enabled a phased reduction in the price of the malaria vaccine, starting immediately and fully realised by 2028, when the transfer of production between the two companies is complete," it added. Gavi, the Vaccine Alliance CEO Sania Nishtar said, "Our ambition is to protect at least 50 million more children across Africa by the end of 2030, and this collaboration between GSK and Bharat Biotech helps put this goal firmly within reach."
Time of India
3 hours ago
- Time of India
Bharat Biotech, GSK to slash malaria vaccine price
Synopsis Bharat Biotech and GSK will lower the malaria vaccine price to under $5 by 2028. This is due to better processes and more production. They pledged this to Gavi. Bharat Biotech invested over $200 million to boost production. Twelve African countries will use the vaccine by 2025. This aims to help millions of children and families.
